Subject: Original Article | Zolpidem | R5-920 | drug safety | Medicine (General) | sleep initiation and maintenance disorders | United States Food and Drug Administration | insomnia
mesheuropmc: psychological phenomena and processes | musculoskeletal, neural, and ocular physiology
Background: Women have higher morning serum zolpidem concentrations than men after taking an evening dose, potentially leading to increased risk of harm. On 19 April 2013, the United States Food and Drug Administration required labeling changes for zolpidem, recommendin... View more
7 Food and Drug Administration. FDA drug safety communication: FDA approves new label changes and dosing f or zolpidem products and a recommendation to avoid driving the day after using Ambien CR, http://www.fda.gov/Drugs/DrugSafety/ucm352085.htm (2013, accessed 10 August 2015).